Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06220994
Other study ID # 21431-4-01
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date November 15, 2021
Est. completion date May 15, 2025

Study information

Verified date March 2023
Source Beijing Tsinghua Chang Gung Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Intestinal floras and their metabolites are involved in progressing metabolic and cardiovascular diseases. However, currently, articles related to the relationship between intestinal floras and atherosclerosis mainly focus on coronary atherosclerotic disease (CAD) population, or atherosclerosis model animals such as ApoE-/-, LDLR-/- high-fat diet mice, and there are few studies on Chronic limb-threatening ischemia (CLTI). CLTI and CAD have a similar pathological basis of atherosclerosis. It is unclear whether intestinal flora plays an essential role in the occurrence and development of CLTI. This project aims to explore the relation between microorganisms, metabolites, and CLTI.


Description:

This project aims to study the intestinal flora and its metabolites in patients with CLTI, explore whether CLTI patients and CAD patients have their own characteristic flora, analyze the microorganisms and metabolites markers of poor prognosis in patients with CLTI, and screen out the key differential bacteria and metabolites that inhibit the progress of CLTI, in order to provide new insights and research basis for the treatment of CLTI.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 120
Est. completion date May 15, 2025
Est. primary completion date May 15, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Control group: sex - and age-matched healthy people (without history of atherosclerotic plaque, coronary heart disease or stroke). Case group: resting pain for at least 2 weeks with at least one hemodynamic index: ABI<0.4,AP<50mmHg, TP or TCPO2<30mmHg. Tissue defects (ulceration or gangrene) persisted for at least 2 weeks with at least one significant PAD objective evidence: ABI<0.8, AP<100mmHg, TP or TCPO2<60mmHg. Exclusion Criteria: 1. Patients with inflammatory bowel disease, autoimmune diseases, malignancies, infectious diseases, and severe liver and kidney dysfunction (cirrhosis, CKD stage 4 and 5). 2. Patients with thromboembolic angiitis, arterial embolism, and takayasu. 3. Patients who have used probiotics or antibiotics in the last 2 months. 4. After interventional surgery and amputation below the knee or above knee.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Beijing Tsinghua Chang Gung Hosipital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tsinghua Chang Gung Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bacteria or metabolites associated with prolonged survival time without above-knee amputation The relationship between the prognosis and gut microbiota or plasma metabolomics was analyzed. Spearman correlations between CAGs, serum metabolite modules and clinical parameters were calculated using R, and both differential abundances of CAGs and CLTI-associated metabotypes were tested by the Wilcoxon rank sum test. 3years.
Secondary Key bacteria in CLTI Differential bacteria enriched in healthy group but absent in CLTI patients were explored by metagenomic analysis of the gut microbiota. It includes species composition and abundance analysis, beta diversity, differences between groups, and RDA/CCA. up to 1 week
Secondary Key plasma metabolites in CLTI Differential metabolites enriched in healthy group but absent in CLTI patients were explored by non-targeted metabolomics analysis of the gut contents. It includes sample grouping data analysis, metabolites annotation, and screening of differential metabolites. up to 1 week
See also
  Status Clinical Trial Phase
Recruiting NCT05288790 - Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT Phase 2
Recruiting NCT05963659 - Nitrate Modulates Cognitive Impairment Via Oral Microbiota. N/A
Completed NCT04130321 - Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans N/A
Recruiting NCT05929976 - InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Withdrawn NCT04230746 - Effect of Antibiotics on Urinary Microbiome Early Phase 1
Active, not recruiting NCT06289283 - Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
Recruiting NCT05714566 - Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients
Enrolling by invitation NCT06225336 - Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) Phase 1
Recruiting NCT05068362 - Auricular Reconstruction in Microtia by Medpor Implant Following Tissue Expansion N/A
Completed NCT02224677 - Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)
Not yet recruiting NCT05615116 - Clinical Study on the Distribution of Digestive Tract Microbiota Before and After Ileocecal Resection in Crohn's Disease
Completed NCT00958802 - Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies Phase 0
Recruiting NCT06087874 - Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice Phase 2
Suspended NCT03624608 - Evaluation of the Auryzon Devices in the Optimization of Ear and Nose Reconstruction Procedures N/A
Not yet recruiting NCT06394687 - The Digestion of Protein Powders in Healthy Participants Using SIMBA and LIMBA Capsule N/A
Completed NCT05417360 - Akkermansia and Weight Maintenance N/A
Recruiting NCT02518035 - Silicone Gel to Improve Scar in Microtia Patients Phase 4
Recruiting NCT06072040 - Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia Phase 1/Phase 2
Recruiting NCT06078566 - Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 Phase 1/Phase 2
Not yet recruiting NCT03729427 - Rib Microtia and the Erector Spinae Plane (ESP) Block N/A